TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05010122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04580914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with IntellaNav StablePoint Ablation Catheter
Description: Patients will be treated with an ablation catheter
Study: NCT06084754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field
Description: pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Vancomycin IV injection 1gm divided 250mg every 6hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Vancomycin IV injection 1gm divided 250mg every 6hours
Study: NCT04985409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
Study: NCT05617924

Intervention type: PROCEDURE
Intervention: Physical Therapy
Description: Therapy methods using physical agents in treatment

Intervention type: PROCEDURE
Intervention: Physical Therapy
Description: Therapy methods using physical agents in treatment

Intervention type: PROCEDURE
Intervention: Physical Therapy
Description: Therapy methods using physical agents in treatment
Study: NCT05645978

Intervention type: DEVICE
Intervention: Pacemaker insertion
Description: Patients who underwent pacemaker insertion between January 2015 and December 2020
Study: NCT06457776

Intervention type: PROCEDURE
Intervention: Dental management
Description: The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
Study: NCT06347068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 300 mg/m2 IV will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine 30 mg/m2 IV will be given.
Study: NCT06060067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection on Day 1 and Day 90 of the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection on Day 1 and Day 90 of the study

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
Study: NCT06664333

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care.
Study: NCT06666257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy
Description: The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be send automatically to participants. For the CGM piece, participants will wear unblinded CGM devices and have access to CGM linked app features that allow insights and reactivity to personal glycemic data

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Monitoring to Support Healthy Weight Gain in Pregnancy
Description: The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be send automatically to participants
Study: NCT05975008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness
Description: Brief virtual mindfulness-based intervention
Study: NCT05701748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimuli
Description: placement of oral pacifier, electrical stimulation, and laryngoscopy
Study: NCT06665737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early receiving G-CSF group
Description: Early receiving G-CSF group will be given within 72 hours post chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Late receiving G-CSF group
Description: Late receiving G-CSF group will be given after 72 hours post chemotherapy
Study: NCT05281939

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Artificial intelligence diagnosis
Description: Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
Study: NCT06436872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informing patients with using a booklet
Description: The intervention group was informed before discharge and was given an information booklet. A phone number was given so that the researcher could contact the nurse. In the 4th week, 8th week and 12th week, information was given according to the information needs of the patient and caregiver.
Study: NCT06372002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Description: The intervention will consist of the Spanish adapted version of Cognitive Stimulation Therapy (CST) followed by the Maintenance CST program.~CST is a cognitive intervention for treating mild to moderate dementia consisting of fourteen 45-minute group sessions that take place twice a week for 7 weeks. Each session follows a main topic (reminiscing about the person's life, current events, word games...) and is led by two group facilitators. The same structure is followed in every CST session: 1. Introduction (5 minutes). 2. Main Activity (25 minutes). 3. Closing (5 minutes).~The Maintenance CST program follows the principles and structure of the original CST program and consists of 24 sessions, one per week, that will be administered after the original program.~The topic, activities, and materials required for each session are specified in the CST-ES manuals, which also provide the key principles that should guide the intervention and other information necessary for its implementation.
Study: NCT05381116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avation System
Description: Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Avation System
Description: Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
Study: NCT06016088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSP-1502
Description: RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
Study: NCT06015750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate will be administered SC or orally weekly for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib will be administered via IV bolus or SC, as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg will be administered via IV monthly through initial 74 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid will be given orally as long as methotrexate is being dosed.
Study: NCT06603818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
Study: NCT04988724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training with aerobic and strength training, 30 min per session
Study: NCT06603818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will occur on Days 1, 3, and 5 of Cycle 1 only
Study: NCT06609005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-9956
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
Study: NCT05148117

Intervention type: DIAGNOSTIC_TEST
Intervention: Suspected Sepsis Group - Diagnostic Measurements
Description: Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Control Group - Diagnostic Measurements
Description: Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
Study: NCT04984265

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT targeting the area of the circuit of Ventricular Tachycardia
Study: NCT05732506

Intervention type: DRUG
Intervention: Edoxaban
Description: There are not intervention.
Study: NCT05999045

Intervention type: OTHER
Intervention: Singing activity
Description: The singing activity will involve a 1-hour performance, rehearsal, or lesson.
Study: NCT04712305

Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required

Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required
Study: NCT05951504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
Study: NCT06502574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: The mobile application prepared for rational drug use andchronic disease self-management, suitable for use by olderadults, will be required to be used for 6 months.
Study: NCT05552560

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients.
Study: NCT05466526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High frequency deep sclerotomy (HFDS)
Description: The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
Study: NCT05918692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-500
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-500
Description: Investigational Product
Study: NCT06030076

Intervention type: DRUG
Intervention: Tildrakizumab
Description: As provided in real-world clinical practice.
Study: NCT06594523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denifanstat
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denifanstat
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Tablet
Study: NCT06596291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG110A
Description: Participants treated with EG110A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG110A
Description: Participants treated with EG110A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG110A
Description: Participants treated with EG110A
Study: NCT06593210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant, non-live RSV vaccine
Description: One dose of arexvy vaccine to transplant recipients.
Study: NCT06598631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volenrelaxin
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volenrelaxin
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volenrelaxin
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06592547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous metoprolol tartrate
Description: An intravenous beta-blockers, recieved FDA approval

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care (in control arm)
Description: Standard care according to surviving sepsis campaign
Study: NCT06589804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06601127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiprogrel+Aspirin
Description: Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiprogrel+Aspirin
Description: Drug: Tiprogrel and Aspirin Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel+Aspirin
Description: Day 1, loading dose of Clopidogrel and loading dose of aspirin; Day 2-21, daily maintenance dose of Clopidogrel and daily maintenance dose of aspirin; D22-90: daily maintenance dose of Clopidogrel.
Study: NCT06585774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA034176
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral/IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral/IV Infusion
Study: NCT06587386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First patient Bupivacaine liposome and next patient Bupivacaine liposome
Description: This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome concentration depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a concentration of 0.443% w/v (15ml). Subsequently, if motor function was preserved, the next patient received a lower concentration (increased by 0.05% w/v) with a probability of b=0.11; or the same concentration with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower concentration (decreased by 0.05% w/v).
Study: NCT06657456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterol-rich extract
Description: Experimental product: extract rich in phytosterols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product with identical characteristics to the experimental product.